Background:
Breast cancer associated protein 2 (BCA2) is a ubiquitin E3 ligase found in invasive breast cancer. Studies have shown that by decreasing its activity, breast cancer cell growth and invasiveness are diminished. Targeting this ligase and inhibiting its activity could play a role in treatment of breast cancer. A molecular approach to inhibiting this ligase is a new methodology that could circumvent drug resistance and be used safely, with few side effects.
Technology
BCA2 is a molecule containing a certain zinc-binding domain. By disabling this zinc binding area, the BCA2 ligase is no longer active. The chemical disulfiram has been found to be effective in ejecting the zinc from the binding region, causing a decrease in BCA2 activity. The technology consists of using disulfiram and analogs to inhibit the BCA2 molecule’s activity as a treatment for breast cancer.
Commercial applications
Stage of Development:
Pre-clinical, cell culture studies performed
Competitive advantages
Intellectual Property Status
Patent application filed